Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Michael B. Streiff, Bjorn Holmstrom, Dana E. Angelini, Aneel A. Ashrani, Tyler W. Buckner, Robert Diep, Kleber Yotsumoto Fertrin, Annemarie E. Fogerty, Nicolas Gallastegui, Radhika Gangaraju, Cristhiam M. Rojas‐Hernandez, Samuel Z. Goldhaber, Ibrahim Ibrahim, Timothy Kubal, Andrew D. Leavitt, Ming Y. Lim, Janelle Mann, Simon Mantha, Colleen Morton, Alex Nester, Andrew O’Brien, Thomas L. Ortel, Alexander B. Pine, Allyson M. Pishko, M. Ranade, Amirali Salmasi, Jordan K. Schaefer, Eliot C. Williams, Geoffrey D. Wool, Theodore Wun, Sarah Montgomery, Jamie Nguyen, Deborah A. Freedman-Cass, Bailee Sliker
Abstract
The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease provide strategies for the prevention, diagnosis, and treatment of venous thromboembolism (VTE) in adult patients with cancer. VTE is a common and life-threatening condition in patients with cancer, and its management often requires multidisciplinary efforts. The NCCN panel is comprised of specialists spanning various fields, including cardiology, hematology, medical oncology, internal medicine, interventional radiology, and pharmacology. The content featured in this issue specifically addresses the evaluation and recommended treatment options outlined in the NCCN Guidelines for the diverse subtypes of cancer-associated VTE.